Trial Profile
A phase I study to evaluate safety and feasibility of pharmacokinetically (PK)-guided dosing of pazopanib in patients with solid tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Dec 2015
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 19 Dec 2015 New trial record